- Home
- ANIX vs COEP Comparison
ANIX vs COEP Comparison
Compare ANIX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | COEP |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 72.7M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | COEP |
|---|---|---|
| Price | $2.95 | $12.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 104.2K | 30.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $6.32 |
| 52 Week High | $5.46 | $21.41 |
Technical Indicators
Market Signals| Indicator | ANIX | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 48.81 |
| Support Level | $2.74 | $10.83 |
| Resistance Level | $3.11 | $13.12 |
| Average True Range (ATR) | 0.15 | 0.83 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 39.44 | 52.61 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.